Brief: Lipidor Updates On Phase III Clinical Trial Of Drug Candidate AKP02 For Treatment Of Psoriasis

Lipidor AB

22/04/2021 08:32

April 22 (Reuters) - Lipidor AB  LIPI.ST :
    * LIPIDOR - UPDATE ON THE COMPANY'S PHASE III CLINICAL TRIAL
OF
DRUG CANDIDATE AKP02 FOR TREATMENT OF PSORIASIS
    * RESULTS FROM STUDY ARE EXPECTED IN FIRST HALF OF 2022.
    * POSITIVE RESULTS FROM PHASE III STUDY WITH ITS PREDECESSOR
AKP01, BASED SOLELY ON CALCIPOTRIOL, SHOW THAT LIPIDOR'S AKVANO®
TECHNOLOGY WORKS WELL FOR TREATMENT OF PSORIASIS
    * OBSERVER-BLIND AND PLACEBO-CONTROLLED PHASE III STUDY IS
EXPECTED TO HAVE FIRST PATIENT IN-TREATMENT DURING SUMMER WITH
REPORTING IN FIRST HALF OF 2022
    * TO DATE, COVID-19 PANDEMIC HAD LIMITED EFFECT ON
OPERATIONS, BUT
COMPANY MAY NEED TO REVISE ITS SCHEDULES IF PANDEMIC IS
PROLONGED.
    * PRECLINICAL STUDIES SHOW THAT BETAMETHASONE ALSO WORKS
WELL IN
AKVANO®, WHICH IS A GOOD PREREQUISITE FOR COMBINATION
PREPARATION AKP02.

Source text for Eikon:  ID:nWkrbMfjW4 
Further company coverage:  LIPI.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))